

From: [Jarvis, Candace](#)
To: [Evans, Jill A. \(JAEvans@lifesouth.org\)](#)
Cc: [Heidaran, Mohammad](#); [Dollins, Eric](#); [Jarvis, Candace](#)
Subject: BLA 125432/Life South: Draft Labeling
Date: Monday, June 10, 2013 11:36:12 AM
Attachments: [BLA 125432_20130531_6_10_2013.docx](#)

Good morning Jill,

Please find attached the Final FDA draft for the Package Insert. Please review, accept the track changes and remove bubbles for the items you feel are acceptable and understand. Please send the revised version back to us by tomorrow morning at 10 am to ensure a timely review.

With regard to the package labeling, please change Hetastarch to Hydroxyethylstarch with a capital H and should be placed on a separate line like Hetastarch was before. We will need this too by 10 am tomorrow morning.

We further request that you provide a revised container label by removing the wording in the middle stating "REMOVE THIS LABEL BEFORE PLACING ON BAG". We will need this too by 10 am tomorrow morning.

Please let me know if you have any questions.

Regards,

*Candace N. Jarvis
Regulatory Project Manager
FDA/CBER/OCTGT
1401 Rockville Pike HFM-705
Rockville, MD 20852
Phone: 301-827-6536
Fax: 301-827-9796
candace.jarvis@fda.hhs.gov*

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.